722.F ANTENGENE CORP. DL-0001

Healthcare Biotechnology Frankfurt Exchange
0.3000 EUR
Close of Nov 11, 2026
0.2840 0.6450
Market cap
EUR 183M
P/E
30.0x
P/B
1.50x
ROE
-37.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 722.F undervalued?

Graham number
Price0.3000
Graham value0.2119
Premium41.6%

722.F trades 41.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ANTENGENE CORP. DL-0001 fundamental analysis

No fundamental analysis for ANTENGENE CORP. DL-0001 yet.

ANTENGENE CORP. DL-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ANTENGENE CORP. DL-0001

Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage …

Full company profile